Active Biotech Regains Rights to Laquinimod to Continue Studying Its Potential
Active Biotech. has regained global development and commercialization rights of laquinimod, an investigational immunotherapy for neurodegenerative diseases, including Huntington’s disease (HD) and multiple sclerosis (MS). The move came after Teva Pharmaceutical, the company that previously held laquinimod’s rights, decided not to continue its clinical development. After several years…